Newcomer, JW. Metabolic syndrome and mental illness. Am J Manag Care
2007; 13: S170–7.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation
2002; 106: 3143–421.
Lakka, HM, Laaksonen, DE, Lakka, TA, Niskanen, LK, Kumpusalo, E, Tuomilehto, J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA
2002; 288: 2709–16.
Ford, ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care
2005; 28: 1769–78.
Casey, DE, Haupt, DW, Newcomer, JW, Henderson, DC, Sernyak, MJ, Davidson, M, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry
2004; 65 (suppl 7): 4–18.
Newcomer, JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs
2005; 19 (suppl 1): 1–93.
Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry
1999; 156: 1686–96.
Lund, BC, Perry, P, Brooks, JM, Arndt, S.
Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidaemia and hypertension: a claims based approach. Arch Gen Psychiatry
2001; 58: 1172–6.
Lamberti, JS, Olson, D, Crilly, JF, Olivares, T, Williams, GC, Tu, X, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry
2006; 163: 1273–6.
Ahmed, M, Hussain, I, O'Brien, SM, Dineen, B, Griffin, D, McDonald, C.
Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Ir J Med Sci
2008; 177: 205–10.
Grundy, SM, Brewer, HB Jr, Cleeman, JI, Smith, SC Jr, Lenfant, C.
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation
2004; 109: 433–8.
Straker, DO, Correll, CU, Kramer-Ginsberg, E, Abdulhamid, N, Koshy, F, Rubens, E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry
2005; 162: 1217–21.
Taylor, D, Paton, C, Kerwin, R.
The Maudsley Prescribing Guidelines (9th edn). Taylor & Francis, 2007.
Covell, NH, Jackson, CT, Weissman, EM. Health monitoring for patients who have schizophrenia. Summary of the Mount Sinai Conference recommendations. Postgrad Med
2006; Spec No: 20–6.
Alberti, KG, Zimmet, P, Shaw, J.
The metabolic syndrome – a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med
2006; 23: 469–80.
Katzmaryk, PT, Leon, AS, Wilmore, JH, Skinner, JS, Rao, DC, Rankinen, T, et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med Sci Sports Exerc
2003; 35: 1703–9.
Volek, JS, Feinman, RD. Carbohydrate restriction improves the features of metabolic syndrome. metabolic syndrome may be defined by the response to carbohydrate restriction. Nutr Metab (Lond)
2005; 2: 31.
Rubins, HB. Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk
2000; 7: 339–45.
Barter, PJ, Rye, KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Arterioscler Thromb Vasc Biol
2008; 28: 39–46.
Shields, TM, Hennekens, CH. Management of metabolic syndrome: aspirin. Endocrinol Metab Clin North Am
2004; 33: 577–93.